Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Jan 04, 2022 1:12pm
107 Views
Post# 34282237

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Possible chinese partner?

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Possible chinese partner?I'm leaning toward giving them until the end of the month to convince me I shouldn't bail and invest elsewhere.  I can always buy back in, and right now, I'm not convinced the share price will see any significant staying power on a pop on good news.  Meanwhile, I'm making money everywhere else but here.  The market obviously thinks management has made a huge mistake by not keeping it informed.  The proof is in the share price and volume.  Maybe there is some legitimate reason the BOD has to keep so many helpful clues so close to the vest that's protecting us from something we can't see and would not be good temporarily, but I can't see it.  

I still want to know more about why those options were granted the way they were.  I'm not sure I had clarity on that issue based on the responses here.  Seems it could have been a slimy play or nothing unusual.  That combined with the appearance of Paul and the BOD misleading the market on the other topics you all have discussed has led me to conclude I might not be able to trust the company.  That's beginning to become a major issue for me withe the lack of communication.  
<< Previous
Bullboard Posts
Next >>